April 23, 2018 7:58am
PSTI closed Friday at $1.20 (-$0.04) and is UP +$0.04 in the pre-market
The 5-year joint project was granted $2.5 million from the U.S. NIH
Data from these studies will support BLA filing for marketing approval of PLX-R18 in the treatment of ARS or will it?
The U.S. National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), has awarded a $2.5 million grant to Indiana University to conduct studies of PSTI’s PLX-R18 cell therapy in the treatment of acute radiation syndrome (ARS).
The goal of this project is to extend the PLX-R18 ARS studies to include examination of survival efficacy in additional populations, such as geriatric and pediatric, and to compare the effectiveness and examine interactions with other drugs, such as Granulocyte-Colony Stimulating Factor (G-CSF).
Let’s NOT get to ahead of data collection; during the first year of this 5-year research agreement MIGHT not will support PSTI’s Biologics License Application (BLA) filing with the FDA for marketing approval of PLX-R18 in the treatment of ARS. PSTI just loves the HYPERBOLE!
The $2.5 million, 5-year research collaboration agreement will be performed in conjunction with Indiana University and as part of this agreement; Pluristem will be reimbursed for supplying PLX-R18 cells for these studies.